Mercaptopurine Aspen Pharma Trading Limited (Mercaptopurine)

Mercaptopurine inhibits the enzyme hypoxanthine‑guanine phosphoribosyltransferase, blocking the synthesis of purine nucleotides. This reduces DNA and RNA production, limiting the proliferation of rapidly dividing cells such as leukemic blasts and activated immune cells.

The dose of Mercaptopurine is individualized. A qualified prescriber determines the appropriate amount based on the specific indication, patient weight, age, renal and hepatic function, and other clinical factors.

Mercaptopurine is classified as pregnancy category D, indicating evidence of fetal risk. It should be used only when the potential benefit justifies the risk. Breastfeeding is generally not recommended because the drug can be excreted in milk.

To order Mercaptopurine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

The most common alternative is azathioprine, another thiopurine. Both drugs share a similar mechanism, but mercaptopurine is often preferred for certain leukemias because it provides more direct antineoplastic activity, whereas azathioprine is primarily used for immunosuppression in autoimmune conditions.

Mercaptopurine tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid exposure to excessive heat or humidity.

Mercaptopurine is administered orally, usually as a tablet or capsule, and should be taken with or without food as directed by the prescribing clinician. Swallow the dosage form whole; do not crush or chew unless specifically instructed.

The most serious risks include severe myelosuppression leading to infection or bleeding, hepatotoxicity with potential liver failure, and rare cases of pancreatitis. Patients should report fever, unusual bruising, jaundice, or severe abdominal pain promptly.

Mercaptopurine should be avoided in patients with known thiopurine methyltransferase (TPMT) deficiency, severe liver disease, uncontrolled infections, or in pregnant women unless the benefit outweighs the risk. It is also contraindicated in individuals with hypersensitivity to the drug.